ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Myopathies"

  • Abstract Number: 2071 • ACR Convergence 2025

    Impact of Diagnostic Delay on Disease Activity and Cumulative Damage in Patients with Idiopathic Inflammatory Myopathies in a Third-level Hospital in Mexico

    valeria cantu1, Rebeca L. Polina-Lugo1, Emmanuel Dominguez-Chapa2, Ana Cecilia Bardan Inchaustegui3, Fernanda M. Garcia-Carrillo4, Daniela A. Mejia-Rodriguez4, Ericka S. Reyna-Hernandez4, Rosa Arvizu-Rivera5, Jesus Alberto Cardenas-de la Garza6 and Miguel Villarreal-Alarcón7, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 2Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 3Universidad Autónoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 4Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, 5Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, 6Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, 7Hospital Universitario UANL, Monterrey, Nuevo León, Mexico

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare and heterogeneous group of autoimmune diseases marked by inflammation of muscle tissue and extramuscular manifestations. Their atypical…
  • Abstract Number: 1201 • ACR Convergence 2025

    Prognostic Significance of 1-Year Pulmonary Function Changes in Myositis-Associated Interstitial Lung Disease

    Shiri Keret1, Silvia Martinez Laverde2, Irada Choudhuri2, Raisa Lomanto Silva3, Eugenia Gkiaouraki2, Tanya Chandra2, Nantakarn Pongtarakulpanit4, Shreya Sriram2, Niladri Bhowmick2, Vaidehi Kothari2, Kaushik Sreerama Reddy2, Eaman Alhassan5, Anushka Aggarwal6, Maha Almackenzie7, Daniel Sullivan2, Sara Faghihi-Kashani8, Koichi Yamaguchi2, Daniel Kass2, Kevin Gibson2, Dana Ascherman9, Siamak Moghadam-Kia5, Chester V. Oddis9 and Rohit Aggarwal10, 1Bnai Zion Medical Center, Atlit, Israel, 2University of Pittsburgh Medical Center, Pittsburgh, 3Massachusetts General Hospital, Boston, MA, 4Mahidol University, University of Pittsburgh, Bangkok, Thailand, 5University of Pittsburgh Medical Center, Pittsburgh, PA, 6Indraprastha Apollo Hospital, New Delhi, India, 7Medical Cities of the Ministry of the Interior, Riyadh, Saudi Arabia, 8UCSF, Mountain View, CA, 9University of Pittsburgh, Pittsburgh, PA, 10University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA

    Background/Purpose: Lung involvement is the most frequent and severe extramuscular complication of Idiopathic Inflammatory Myopathy (IIM). The utility of pulmonary function test (PFT) monitoring for…
  • Abstract Number: 0281 • ACR Convergence 2025

    Anti-IL-6 Autoantibodies and IL-6 Signalling in Idiopathic Inflammatory Myopathies

    Anja Srpcic1, Manca Ogric1, Sasa Cucnik1, Sergej Pirkmajer2, Katja Lakota1 and Katja Perdan Pirkmajer1, 1University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of systemic autoinflammatory diseases that affect muscle tissue, often leading to muscle atrophy, weakness and myalgia.…
  • Abstract Number: 2068 • ACR Convergence 2025

    Comparing characteristics, diagnostics, and treatment in people with different idiopathic inflammatory myopathies using a large representative cohort

    Michael George1, Thomas Riley1, Ellen Romich2, Emily Holladay3, Tim Beukelman4, Shanette Daigle5, Amy Mudano5, Fenglong Xie6, Xiang Guo7, Nicole Kulisek8, Arne Yndestad9, Ashraf Chaudhary8 and Jeffrey Curtis10, 1University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Media, PA, 3University of Alabama at Birmingham, Birmingham, AL, 4Foundation for Advancing Science Technology Education and Research, Hoover, AL, 5Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, 6The University of Alabama at Birmingham, Birmingham, AL, 7Pfizer, Inc, New York, NY, 8Pfizer, Inc, Collegeville, PA, 9Pfizer Inc, Oslo, Norway, Oslo, Norway, 10Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL

    Background/Purpose: Studies of idiopathic inflammatory myopathies (IIM) are often based on the analysis of single cohorts at academic centers. We aimed to identify potential gaps…
  • Abstract Number: 1199 • ACR Convergence 2025

    Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (SARDs): Radiologic and Histologic Correlations

    Darya S. Jalaledin1, Aidan pye2, Angela Chang2, Navid Saleh2, Saud AlHajeri3, Beatrice Daviault4, Arusa Shah5, Sabrina Hoa6, Océane Landon-Cardinal7, Alec Yu2, Robert Levy8, Jennifer Wilson9, Charles Poirier4, James Choi2, John Yee2, Hyein Kim2 and Kun Huang10, 1Université de Montréal, Saint-Lambert, QC, Canada, 2University of British Columbia, VANCOUVER, BC, Canada, 3University of British Columbia, Vancouver, Canada, 4University of Montreal, Montreal, QC, Canada, 5University of Montreal, Montreal, BC, Canada, 6University of Montreal, Brossard, QC, Canada, 7Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, 8University of British Columbia, Deerfield, IL, 9UBC, Vancouver, BC, Canada, 10University of British Columbia, Vancouver, Surrey, BC, Canada

    Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) are a major cause of interstitial lung disease (ILD), with high prevalence in inflammatory idiopathic myopathy (IIM), systemic sclerosis…
  • Abstract Number: 2067 • ACR Convergence 2025

    Patterns of Comorbidity in Idiopathic Inflammatory Myopathies: A Cross-sectional Analysis of Disease Burden and Risk Factors

    Ilke Coskun Benlidayi1, Meghna Lama2, Oladipo Kunle Afolayan2, Meera Shah3, Manali Sarkar4, Tamar Rubinstein5, Aleksandra Opinc-Rosiak6, Rada Miskovic7, Marcin Milchert8, Dimitri Luz Felipe da Silva9, Samuel Katsuyuki Shinjo10, Elena Nikiphorou11, Ioannis Parodis12, Vincenzo Venerito13, Vikas Agarwal14 and Latika Gupta15, 1Cukurova University, Adana, Turkey, 2The University of Texas Health Science Centre at Houston School of Public Health: Houston, Texas, Houston, 3Indraprastha Apollo Hospital, New Delhi, Mumbai, Maharashtra, India, 4Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, 5Albert Einstein College of Medicine, White Plains, NY, 6Medical University of Lodz, Zeromskiego 113, 90-549 Lodz, Poland., Lodz, Poland, 7University of Belgrade; Clinic of Allergy and Immunology, University Clinical Centre of Serbia, Belgrade, Serbia, 8Pomeranian Medical University in Szczecin, Szczecin, Poland, 9University Santo Amaro, São Paulo, Brazil, Sao Paulo, Brazil, 10Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, 11King's College London, London, United Kingdom, 12Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, 13Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, 14Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 15School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom

    Background/Purpose: Comorbidities contribute to the disease burden in idiopathic inflammatory myopathies (IIMs). Understanding their distribution and predictors across IIM subtypes can guide tailored strategies. This…
  • Abstract Number: 1196 • ACR Convergence 2025

    Prevalence of and Factors Associated with Chronic Opioid Use among Individuals with Inflammatory Myopathies

    Anuya Natu1, Haley Zimmerman2, Kristin Wipfler3, Kaleb Michaud4, Yvonne Lee5 and Didem Saygin2, 1John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, 2Rush University Medical Center, Chicago, IL, 3FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 4University of Nebraska Medical Center, Omaha, NE, 5Northwestern University, Chicago, IL

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) can be associated with significant pain and functional impairment. While the use of opioids has been documented in other inflammatory…
  • Abstract Number: 2066 • ACR Convergence 2025

    Psychosocial Factors Strongly Influence Subjective Well-being in Patients with Idiopathic Inflammatory Myopathies

    Meera Shah1, Emilia Naseva2, Tsvetelina Velikova3, Tamar Rubinstein4, Manali Sarkar5, Lavanya Mangla6, Oliver Distler7, Ingrid de Groot8, Lisa Christ9, Carlo Vinicio Caballero Uribe10, Ai Lyn Tan11, Abraham Edgar Gracia Ramos12, Vincenzo Venerito13, Vikas Agarwal14 and Latika Gupta15, 1Indraprastha Apollo Hospital, New Delhi, Mumbai, Maharashtra, India, 2Faculty of Public Health, Medical University of Sofia, 15 Acad. Ivan Evstratiev Geshov, 1606 Sofia; Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, 3Medical Faculty, Sofia University St. Kliment Ohridski, Sofia, Bulgaria, 4Albert Einstein College of Medicine, White Plains, NY, 5Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, 6Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, New Delhi, India, 7Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, 8The Myositis Association, Rotterdam, Netherlands, 9Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Bern, Switzerland, 10Department of Medicine, Hospital Universidad del Norte, Barranquilla, Atlantico, Colombi, Barranquilla, Colombia, 11NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, England, United Kingdom, 12Department of Internal Medicine, General Hospital, National Medical Center “La Raza”, Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990 Mexico City, Mexico., Mexico City, Mexico, 13Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, 14Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, 15School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom

    Background/Purpose: Traditional clinical measures are well established in idiopathic inflammatory myopathies (IIM), yet exploration of subjective well-being (SWB) remains limited. SWB assessment facilitates holistic patient…
  • Abstract Number: 1193 • ACR Convergence 2025

    Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis

    Angela Chang1, Navid Saleh1, Alec Yu1, Darya S. Jalaledin2, Sabrina Hoa3, Robert Levy4, Jennifer Wilson5, Charles Poirier6, John Yee1, James Choi1, Océane Landon-Cardinal7, Hyein Kim8 and Kun Huang9, 1University of British Columbia, Vancouver, BC, Canada, 2Université de Montréal, Saint-Lambert, QC, Canada, 3University of Montreal, Brossard, QC, Canada, 4University of British Columbia, Deerfield, IL, 5UBC, Vancouver, BC, Canada, 6University of Montreal, Montreal, QC, Canada, 7Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, 8The University of British Columbia, Vancouver, BC, Canada, 9University of British Columbia, Vancouver, Surrey, BC, Canada

    Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of idiopathic inflammatory myositis (IIM) and systemic sclerosis (SSc), ranging from subclinical ILD to rapidly progressive…
  • Abstract Number: 0319 • ACR Convergence 2024

    Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis

    Farbod Moghaddam1, Mark Tarnopolsky2, Valérie Leclair3, marie Hudson3, Ross Mitchell4, Katherine Buhler1, Erin Hatcher5, Meifeng Zhang1, Antoine Dufour1, Luiz de Almeida1, Marvin Fritzler6 and May Choi1, 1University of Calgary, Calgary, AB, Canada, 2McMaster University, Hamilton, ON, Canada, 3McGill University, Montreal, QC, Canada, 4University of Alberta, Edmonton, Canada, 5McMaster University, Hamilton, Canada, 6Mitogen Diagnostics Corp, Calgary, AB, Canada

    Background/Purpose: Sporadic inclusion body myositis (sIBM) is often challenging to diagnose because many patients have no known biomarkers (seronegative). Machine learning was applied to identify…
  • Abstract Number: 1160 • ACR Convergence 2024

    Short Form-36 Psychometric Properties in Idiopathic Inflammatory Myopathies: Reliability, Validity and Responsiveness

    shiri keret1, Anushka Aggarwal2, Maha Almackenzie3, Tanya Chandra4, Raisa Silva5, Eugenia Gkiaouraki6, Nantakarn Pongtarakulpanit7, shreya Sriram6, Chester Oddis7 and Rohit Aggarwal8, 1Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, 2Department of Rheumatology, Indraprastha Apollo Hospital, New delhi, NY, 3Division of Rheumatology, Department of Medicine, Medical Cities of the Ministry of the Interior Riyadh, Saudi Arabia, Arlington, VA, 4University of Pittsburgh Medical Center, Pittsburgh, PA, 5Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 6Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 7Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: The quality of life, as measured by the Short Form-36 (SF-36), is reduced in patients with idiopathic inflammatory myopathies (IIM). Although endorsed by the…
  • Abstract Number: 2076 • ACR Convergence 2024

    Comparing the Efficacy of Conventional Immunosuppression and Rituximab in Anti-SRP Myositis: Insights from a Tertiary Care Centre Experience

    ABHILASHA ARVIND MANWATKAR1, Ajith Sivadasan2, adinair Vijakrishnan2, John Antony Jude Prakash3, chandhu aS4, JOHN KUMAR DAS5, Meera S N2, illiasul Ibad k2 and JOHN MATHEW1, 1christian medical college, vellore, Tamil Nadu, India, 2Christian Medical College, vellore, 3Chritian Medical College, Vellore, 4CMC Vellore, Vellore, Tamil Nadu, India, 5Christian Medical College, Vellore, India

    Background/Purpose:  There is a relative scarcity of studies on the effective management of Anti-signal recognition particle (anti-SRP)  myositis. Recent consensus on anti-SRP myositis shows that…
  • Abstract Number: 0327 • ACR Convergence 2024

    Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies

    Samuel Govea-Peláez1, Beatriz Alcalá-Carmona2, Jennifer Balderas Miranda3, Yatzil Reyna-Juárez2, María José Ostos-prado2, Nancy R Mejía-Domínguez2, Guillermo Juarez-Vega4, Jiram Torres Ruiz5 and Diana Gomez-martin6, 1INCMNSZ, Mexico City, Mexico, 2Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, 3Universidad Nacional Autónoma de México, Ciudad de México, Mexico, 4Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 5INCMNSZ, Mexico, Federal District, Mexico, 6INCMNSZ, Mexico City, Federal District, Mexico

    Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have reported chronic pain despite having normal serum muscular enzymes, physician global assessment (PhGA) and MMT8 scores, thus…
  • Abstract Number: 1161 • ACR Convergence 2024

    Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity

    Adriana Miguel-Álvarez1, luis M Amezcua Guerra2, María L Loredo-Mendoza1, Luis H. Silveira Torre3 and Angélica Vargas Guerrero4, 1Instituto Nacional de Cardiología "Ignacio Chávez", México, Distrito Federal, Mexico, 2Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, 3Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, 4Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico

    Background/Purpose: The aim of this study is to assess if there are clinical and serological differences in patients with idiopathic inflammatory myopathies (IIM) according to…
  • Abstract Number: 2078 • ACR Convergence 2024

    Increased RAGE Expression in Myositis

    Madison King1, Rita Spathis2, Elizabeth Bagley1 and Melissa Morales3, 1Binghamton University, Johnson City, NY, 2Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, NY, 3SUNY Binghamton, Johnson City, NY

    Background/Purpose: Myositis is a broad term for a group of rare autoimmune diseases that cause persistent muscle inflammation, weakness, and fatigue. Currently, first-line treatment for…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology